Showing 1 - 9 results of 9 for search 'COST ACCOUNTING', query time: 0.65s Refine Results
  1. 1
    Cost-effectiveness analysis of pembrolizumab versus targeted therapies in advanced melanoma
    Subjects: “...cost-effectiveness...”
    Get full text
    Article
  2. 2
    Pharmacoeconomic analysis of flexible-dose administration regimen of Xeomine® in patients with focal dystonia
    by A. E. Cheberda, D. Yu. Belousov, S. K. Zyryanov
    Published 2018-06-01
    Subjects: “...cost-effectiveness analysis...”
    Get full text
    Article
  3. 3
    Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis
    Subjects: “...cost analysis...”
    Get full text
    Article
  4. 4
    Pharmacoeconomic analysis of Actemra<sup>®</sup> in first-line treatment of rheumatoid arthritis in the modes of combination and monotherapy
    by S. K. Zyryanov, A. E. Cheberda, D. Yu. Belousov
    Published 2018-05-01
    Subjects: “...cost-effectiveness analysis...”
    Get full text
    Article
  5. 5
    Comparative pharmacoeconomic analysis of ceffaroline fosamil in the treatment of complicated skin and soft tissues infections
    by S. K. Zyryanov, D. Yu. Belousov, E. V. Afanasyeva
    Published 2018-05-01
    Subjects: “...cost-effectiveness analysis...”
    Get full text
    Article
  6. 6
    Review the results of pharmacoeconomic trials of antiplatelet drugs in the treatment of patients with acute coronary syndrome
    by S. K. Zyryanov, E. V. Dumchenko
    Published 2018-05-01
    “...-utility». The cost analysis of 62% of the authors consider only direct medical costs account for 19...”
    Get full text
    Article
  7. 7
    Analysis of the structure of consumption of antiplatelet drugs in the Russian pharmaceutical market: 2014-2016
    by S. K. Zyryanov, E. V. Dumchenko
    Published 2018-05-01
    “... of consumption of antiplatelet drugs, the share of original drugs as a whole account for about 60% of consumption...”
    Get full text
    Article
  8. 8
    Clinical and economic efficiency of treatment with dapagliflozin of patients with type 2 diabetes mellitus in Russian health care conditions
    by S. K. Zyryanov, I. N. Dyakov
    Published 2020-04-01
    “... direct and indirect costs were taken into account, and in the second scenario, only direct costs were...”
    Get full text
    Article
  9. 9
    Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease
    “... of the patients was calculated in the framework of ONLS. The calculation was carried out taking into account...”
    Get full text
    Article
Search Tools: Get RSS Feed — Email this Search